Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …

Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by
worsening respiratory symptoms and physiological impairment. Increasing awareness of the …

Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Idiopathic Pulmonary Fibrosis | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …

Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide,
reducing their quality of life and leading to death from respiratory failure within years of …